Activity Overview
There are numerous pharmacologic options for treatment of chronic pain. Some clinicians are hesitant to prescribe these medications due to concerns about drug addiction and adverse events such as respiratory depression.

Unfortunately, some pain has no cure. It may be nociceptive, neuropathic, or disease specific. Left untreated, chronic pain may affect sleep, quality of life, mental health, and productivity. The condition is difficult to diagnose and manage because an individual's perception of his or her pain is subjective, and the cause varies between patients. Community pharmacists are readily available to patients and colleagues for questions regarding pain management. They can assess patients' risk for abuse and optimize treatment strategies for improved patient outcomes. In addition, they provide physicians and staff with important information regarding administration, side effects, drug interaction potential, and efficacy of pharmacologic agents used to address chronic pain. In order to provide this type of care, community pharmacists need an in-depth understanding of all the available and emerging technologies and options for long-acting pain management.This activity will focus on the current state of chronic pain management, various advances in treatment options, and how these issues speak to the pharmacist working in the community setting.

Agenda

10 minutes Introduction and Pre-Webcast Outcomes Survey
Bruce R. Canaday, PharmD, FAPhA, FASHP
35 minutes Current State of Chronic Pain Management:
Current and Emerging Long-Acting Opioids

Lynn Webster, MD, FACPM, FASAM
35 minutes Perspectives for the Community Pharmacist
Sheldon J. Rich, RPh, PhD
10 minutes Faculty Debate and Post-Webcast Outcomes Survey
Bruce R. Canaday, PharmD, FAPhA, FASHP

Goal
This activity has been designed to enhance the community pharmacist's understanding of the existing and emerging pharmacologic treatments for chronic pain; to provide strategies for improving pain control, risk management, and quality of life; and to identify and manage barriers associated with long-acting opioid therapy in order to provide optimal patient outcomes.

Intended Audience
This activity is designed for community pharmacists. No prerequisites required.

Learning Objectives
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Upon the conclusion of this activity, the participant should be able to:

  • REVIEW existing and emerging pharmacologic treatment options for chronic pain.
  • IDENTIFY barriers associated with opioid therapy and methods to overcome these obstacles to optimize treatment.
  • DIFFERENTIATE between new and emerging treatment options relating to emerging opioid therapies.
  • MANAGE symptom control and improve quality of life in patients with chronic pain.
  • REVIEW and DISCUSS retail pharmacy implications of the Risk Evaluation and Mitigation Strategies (REMS) program.

Accreditation Statement
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

Credit Designation Statement
This knowledge-based activity is sponsored by The University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.Successful completion of this knowledge-based educational activity will provide 1.5 contact hours credit (0.15 CEUs). A statement of CPE credit will be available online immediately following successful completion of the activity. Successful completion includes attending the on-line session, completing the pre- and post-test, and completing the educational activity evaluation. For April 27 live webcast: ACPE Program #064-000-10-202-L01-P; for May 13, May 18, June 2, and June 8 home study webcasts: ACPE Program #064-000-10-202-H01-P.

Faculty
Bruce R. Canaday, PharmD, FAPhA, FASHP (Chair)
Clinical Professor and Vice-Chair
Division of Pharmacy Practice and Experiential Education
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina

Lynn Webster, MD, FACPM, FASAM
Utah Academy of Pain Medicine
Lifetree Clinical Research and Pain Clinic
Salt Lake City, Utah

Sheldon J. Rich, RPh, PhD
President–SJR Associates, LLC
Adjunct Clinical Assistant Professor–University of Michigan
Adjunct Assistant Professor–Wayne State University
Palm Beach Gardens, Florida

Policy on Faculty and Provider Disclosure
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the online materials.

Americans with Disabilities Act (ADA)
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Grievance Policy
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Fee Information
There is no fee for this educational activity.

 
     
Home | Contact Us | View Account | Need Help? | Subscription